The FDA has approved GlaxoSmithKline’s new type 2 diabetes drug Tanzeum that employs Novozymes’ Veltis technology to achieve an extended half-life requiring once a week administration. The drug has also recently been approved in Europe as the brand Eperzan.   Novozymes’ VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing f...